Congenital Ichthyosis Market

Market Overview:

The Congenital Ichthyosis market reached a value of US$ 5.0 Million across the top 7 markets (US, EU4, UK, and Japan) in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034.

The Congenital Ichthyosis market has been comprehensively analyzed in IMARC's new report titled "Congenital Ichthyosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Congenital Ichthyosis is a rare genetic disorder characterized by the abnormal development of the skin's outermost layer, known as the epidermis. Individuals suffering from this condition have dry, thickened, and scaly skin resembling fish scales. This hereditary disease is typically present at birth and remains a lifelong challenge for those affected. The symptoms of the ailment can vary in severity, with some patients experiencing mild scaling and others facing more pronounced and widespread skin involvement. The skin's appearance can range from fine scales to larger, plate-like formations, leading to discomfort, itching, and potential skin infections.

Additionally, dry and tight skin can limit mobility and cause physical discomfort. The diagnosis of Congenital Ichthyosis is primarily based on a clinical examination and a thorough medical history. Dermatologists and pediatricians often collaborate to identify characteristic skin features and rule out various other skin disorders with similar symptoms. Additionally, genetic testing is recommended to confirm the diagnosis and determine the specific subtype of the ailment. The escalating cases of genetic mutations in certain genes, particularly those responsible for skin barrier function, leading to the manifestation of chronic skin disorders, are primarily driving the Congenital Ichthyosis market. In addition to this, the inflating utilization of effective treatment modalities, such as emollients, topical retinoids, keratolytics, etc., to alleviate symptoms of the disease and improve skin barrier function is also creating a positive outlook for the market. These medications aim to moisturize and exfoliate the affected skin, reducing scaling and promoting a smoother skin texture. Moreover, the widespread adoption of supportive therapies, including regular bathing and moisturizing routines, which can manage the condition and prevent exacerbations in patients, is also bolstering market growth. Apart from this, the rising usage of physical and occupational therapies, since they aid in enhancing motor skills, mobility, and overall quality of life for individuals suffering from congenital ichthyosis, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which involves introducing functional genetic material into the skin cells to correct the mutated genes responsible for the disorder, thereby providing a long-term and targeted solution for patients, is expected to drive the Congenital Ichthyosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Congenital Ichthyosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Congenital Ichthyosis and represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any stake or are planning to foray into the Congenital Ichthyosis market in any manner.

Recent Developments:

• In March 2024, at the 2024 AAD Annual Meeting, Timber Pharmaceuticals, Inc., a subsidiary of LEO Pharma, presented the recent preliminary results of TMB-001 for the treatment of moderate-to-severe Congenital Ichthyosis (CI).
• In February 2024, Timber Pharmaceuticals stated in its press release about the Phase III clinical development stage for Isotretinoin, aimed at addressing Harlequin Ichthyosis (Autosomal Recessive Congenital Ichthyosis 4B).
• In January 2024, LEO Pharma announced the conclusion of its acquisition of the strategic asset TMB-001 and selected assets from Timber Pharmaceuticals to develop a topical treatment for several moderate to severe subtypes of congenital ichthyosis.

Key Highlights:

• Congenital Ichthyosis comprises inherited skin disorders characterized by challenges in keratinization treatment. The global prevalence of Congenital Ichthyosis is estimated to affect approximately 1 in 200,000 to 300,000 births.
• The two most prevalent forms of ichthyosis are autosomal (pseudo-)dominant ichthyosis vulgaris (IVU) and X-linked recessive ichthyosis (XRI), with approximate frequencies of 1 in 300 and 1 in 2500 for males, respectively.
• Congenital Ichthyosiform erythroderma manifests from birth, whereas X-linked ichthyosis typically emerges in males and starts around 3 to 6 months after birth.

Drugs:

Inetagugene Geperpavec, previously known as KB105, is an HSV-1 viral vector that cannot replicate and integrate into the host genome. It functions by expressing human transglutaminase 1 (TGM1). Currently, it is undergoing Phase I/II clinical trials for the treatment of ichthyosis disease. Additionally, it has received orphan drug designation from the FDA.

Isotretinoin, an oral medication designed mainly to affect sebaceous glands, is frequently recommended for treating severe acne. Presently, it's in phase 3 clinical trials as a potential treatment for Congenital Ichthyosiform Erythroderma. This drug is classified as a small molecule and is manufactured by Timber Pharmaceuticals.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the congenital ichthyosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the congenital ichthyosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current congenital ichthyosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the congenital ichthyosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the congenital ichthyosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the congenital ichthyosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of congenital ichthyosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of congenital ichthyosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of congenital ichthyosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with congenital ichthyosis across the seven major markets?
• What is the size of the congenital ichthyosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of congenital ichthyosis?
• What will be the growth rate of patients across the seven major markets?
   

Congenital Ichthyosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for congenital ichthyosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the congenital ichthyosis market?
• What are the key regulatory events related to the congenital ichthyosis market?
• What is the structure of clinical trial landscape by status related to the congenital ichthyosis market?
• What is the structure of clinical trial landscape by phase related to the congenital ichthyosis market?
• What is the structure of clinical trial landscape by route of administration related to the congenital ichthyosis market?